Kura Oncology (NASDAQ:KURA) Shares Up 3.9%

Kura Oncology, Inc. (NASDAQ:KURA) shares traded up 3.9% on Wednesday . The company traded as high as $20.95 and last traded at $20.95. 64,472 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 950,172 shares. The stock had previously closed at $20.16.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on KURA. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. Stifel Nicolaus cut their price objective on Kura Oncology from $28.00 to $26.00 and set a “buy” rating for the company in a report on Friday, August 9th. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a report on Monday, August 12th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat.com, Kura Oncology presently has an average rating of “Moderate Buy” and an average target price of $30.60.

Kura Oncology Price Performance

The company’s 50-day moving average price is $20.28 and its two-hundred day moving average price is $20.63. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94. The company has a market capitalization of $1.61 billion, a P/E ratio of -9.71 and a beta of 0.84.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.04. During the same period in the prior year, the company earned ($0.53) earnings per share. The company’s revenue was up .0% compared to the same quarter last year. As a group, sell-side analysts expect that Kura Oncology, Inc. will post -2.45 EPS for the current year.

Hedge Funds Weigh In On Kura Oncology

Hedge funds have recently bought and sold shares of the company. Avoro Capital Advisors LLC increased its stake in shares of Kura Oncology by 29.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after purchasing an additional 870,000 shares during the last quarter. BVF Inc. IL raised its stake in Kura Oncology by 9.5% during the fourth quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock worth $106,027,000 after acquiring an additional 642,245 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Kura Oncology by 50.1% in the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after acquiring an additional 577,732 shares during the last quarter. Affinity Asset Advisors LLC boosted its stake in shares of Kura Oncology by 281.4% in the 1st quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company’s stock valued at $15,581,000 after purchasing an additional 538,957 shares in the last quarter. Finally, Verition Fund Management LLC bought a new stake in shares of Kura Oncology during the 4th quarter valued at approximately $6,695,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.